glp-1 treatment henderson Amycretin — a novel obesity that targets both and amylin receptors — has shown early success in phase 1 testing and will be advanced into phase 3 testing. http://ms.spr.ly/6185SLoJD have resource for achieving sustainable Weight Management Henderson & Las

Such symptoms should be monitored, and any of them continuing should warrant a visit to the Diabetes Specialist Dr Moxit Shah

Patients with severe kidney disease or end-stage renal disease may not be appropriate candidates for this therapy, particularly if they have significant fluid retention or are prone to dehydration

most symptoms improve with time, but rare risks include severe allergic reactions and (very rarely) pancreatitis. How quickly do GLP-1 drugs start to work for weight loss and inflammatory symptoms

Journal of atherosclerosis and thrombosis

One 2026 narrative review concluded that GLP-1 receptor agonist therapy is associated with meaningful nutritional deficiencies and that individualized nutritional assessment and lab evaluation may be appropriate, especially in people at higher risk of malnutrition

10.1590/1984-3143-ar2020-0520 58